Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03107377 · ClinicalTrials.gov registry record · Phase 2
Phase 2B/3 Double-blinded Placebo-controlled
A Phase 2 study, sponsored by Evofem.
- Completed
- Registry status
- Phase 2
- Development phase
- 860
- Enrollment target
NCT03107377: Completed Phase 2 study, sponsored by Evofem.
NCT03107377 is a Phase 2 study that has completed, run by Evofem. The registered enrollment target is 860 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (547% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03107377, a Phase 2 study, has completed, sponsored by Evofem.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 860 participants
- Enrollment target
Study Summary
Phase 2B double-blind placebo-controlled efficacy trial of EVO100 (previously known as Amphora ® Gel) for the prevention of acquisition of urogenital Chlamydia trachomatis infection
Primary Outcome
Proportion of subjects who experience urogenital CT infection during the study intervention period (incident infection of CT).
Interventions
- DRUG Placebo
- DRUG EVO100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2017-11-03 |
| Est. Completion | 2019-08-22 |
| Phase | Phase 2 |
What the finished NCT03107377 record still lists
NCT03107377 is an interventional study that assigns participants to a tested intervention. The registered 860 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (547% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03107377 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03107377 about?
NCT03107377 is a clinical study titled "Phase 2B/3 Double-blinded Placebo-controlled". Phase 2B double-blind placebo-controlled efficacy trial of EVO100 (previously known as Amphora ® Gel) for the prevention of acquisition of urogenital Chlamydia trachomatis infection
What is the current status of trial NCT03107377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 860 participants. The study started on 2017-11-03. Estimated completion is 2019-08-22.
What interventions are being tested in trial NCT03107377?
The interventions under investigation include: Placebo (DRUG), EVO100 (DRUG).
Who is sponsoring clinical trial NCT03107377?
This trial is sponsored by Evofem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03107377's enrollment target sits among peer trials
860 33rd of 2000 higher than 1,966 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04541381 · 860 participants · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
- NCT05211895 · 860 participants · Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- NCT06161025 · 860 participants · Phase 2
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- NCT06541574 · 860 participants · Phase 2
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI